Overview
Contrave combines naltrexone and bupropion in an extended-release tablet, and it approaches weight management from an angle no GLP-1 does: it targets the reward and craving pathways rather than gastric emptying and satiety hormones. For patients whose eating is driven more by craving than by hunger volume, that mechanistic difference is not a technicality.
The pricing is refreshingly plain. The manufacturer states that all patients may pay $99 or less, with the price of Contrave set at $99 per month with free shipping through the CurAccess programme run by Currax Pharmaceuticals. Where insurance covers Contrave, it may cost less: eligible commercially insured patients may pay $20 to $199 per 30-day fill depending on their copay obligation, and savings card material describes paying as little as $20 out of pocket.
Compare that with the alternatives. Without the manufacturer programme, retail pricing has been reported around $742 to $836 for a common version, with discount programmes bringing that down to roughly $199. Some pharmacy channels have listed retail around $178 with typical customer costs near $50. The manufacturer’s $99 flat rate with free shipping is therefore not a marketing gimmick — it is the sensible default route for most cash-paying patients.
The trade-off is efficacy and tolerability. Contrave produces less weight loss than GLP-1 therapy, and bupropion carries its own considerations including seizure risk and psychiatric warnings, while naltrexone is contraindicated with opioid use. Like Qsymia, this is a medication that needs a real clinical assessment rather than a menu selection — but for the right patient it is effective, approved, oral and genuinely affordable.
What Makes Contrave Different
It Targets Cravings, Not Just Appetite Volume
Naltrexone and bupropion act on reward and craving pathways rather than on gastric emptying and satiety hormones the way GLP-1s do. For patients whose eating is craving-driven rather than hunger-driven, that is a genuinely different clinical proposition.
A Genuinely Flat $99 With Free Shipping
The manufacturer states all patients may pay $99 or less, with Contrave at $99 per month and free shipping through the CurAccess programme. No dose ladder, no membership, no commitment tier — a rarity in weight management pricing.
Insured Patients May Pay Substantially Less
Eligible commercially insured patients may pay $20 to $199 per 30-day fill depending on their copay obligation, with savings card material describing as little as $20 out of pocket. Check your coverage before defaulting to the cash programme.
A Real Option When GLP-1s Are Not
For patients who cannot tolerate GLP-1 gastrointestinal effects, cannot afford GLP-1 pricing, or are not clinically appropriate for them, Contrave is an FDA-approved alternative with a completely different mechanism rather than a weaker substitute.
✓ Pros
- •FDA-approved for chronic weight management — full agency review of safety, efficacy and manufacturing
- •Flat $99 per month with free shipping — through the manufacturer CurAccess programme
- •No dose-based price escalation — one price regardless of titration stage
- •Insured patients may pay as little as $20 — per 30-day fill depending on copay obligation
- •Different mechanism from GLP-1s — targets reward and craving pathways
- •Oral extended-release tablet — no injection required
- •Manufacturer home delivery — shipped directly with the programme price
- •An option for craving-driven eating — where GLP-1 satiety mechanisms may fit less well
✗ Cons
- •Less weight loss than GLP-1 therapy — a real efficacy gap against semaglutide and tirzepatide
- •Bupropion carries seizure risk — and is contraindicated in certain patients
- •Psychiatric warnings apply — bupropion has documented neuropsychiatric considerations
- •Naltrexone is contraindicated with opioid use — including opioid pain management
- •Retail pricing outside the programme is very high — reported around $742 to $836
- •Requires genuine clinical assessment — the contraindication list is substantial
- •Twice-daily dosing at maintenance — a higher pill burden than once-daily options
- •Gradual titration required — several weeks before reaching the maintenance dose
Our #1 Recommended Provider
Contrave is well priced and mechanistically distinct. If GLP-1 therapy is accessible and appropriate for you, the weight-loss difference is substantial — Coreage RX offers semaglutide and tirzepatide at the same flat $99.
Medications Offered
Brand-Name or Compounded?
Brand-name, FDA-approved. Contrave is an approved oral weight-management medication combining naltrexone and bupropion in an extended-release tablet. It is not a GLP-1 and not compounded — it has full FDA review of safety, efficacy and manufacturing quality. Its mechanism targets reward and craving pathways rather than satiety hormones.
Contrave (naltrexone HCl / bupropion HCl ER)
$99/month with free shipping via the CurAccess programmeAn extended-release tablet combining an opioid antagonist with an antidepressant that has weight effects, targeting reward and craving pathways. Titrated gradually over several weeks to the maintenance dose, which is taken twice daily.
Contrave with commercial insurance
$20 to $199 per 30-day fillEligible commercially insured patients may pay between $20 and $199 per 30-day fill of 120 pills or less, depending on their copay obligation. Savings card material describes paying as little as $20 out of pocket. Check your coverage before defaulting to the cash programme.
Contrave at retail without programme pricing
Reported around $742 to $836Retail pricing outside the manufacturer programme is very high. Discount programmes have brought this to roughly $199, and some pharmacy channels list retail around $178 with typical customer costs near $50. The manufacturer $99 programme is the sensible default for cash-paying patients.
Two contraindication areas need a direct conversation before starting. Bupropion carries seizure risk and neuropsychiatric warnings, so seizure history, eating disorder history and mental health history all matter. Naltrexone is contraindicated with opioid use — including opioid pain management — so disclose every medication you take.
Pricing, Membership & Medication Fees
| Cost Item | What You Pay |
|---|---|
| Manufacturer CurAccess programme | $99 per month with free shipping; the manufacturer states all patients may pay $99 or less |
| Eligible commercially insured patients | $20 to $199 per 30-day fill of 120 pills or less, depending on copay obligation |
| Savings card | Material describes paying as little as $20 out of pocket |
| Retail without programme pricing | Reported around $742 to $836 for a common version |
| Discount programme pricing | Reported around $199 for a 30-day supply |
| Pharmacy channel pricing | Some channels list retail around $178 with typical customer costs near $50 |
| Dose escalation surcharge | None — the programme price does not change with titration stage |
| HSA / FSA | Prescription costs are commonly HSA/FSA eligible; confirm with your plan administrator |
The spread between routes is enormous — $20 with good insurance, $99 through the manufacturer programme, and $742 or more at retail without either. Nobody should be paying retail. Check your insurance first, then default to the CurAccess programme, and compare a discount card before accepting anything above $99.
How Contrave Works
Disclose Every Medication, Especially Opioids
Naltrexone is contraindicated with opioid use, including opioid pain management. If you take any opioid medication, or expect to need one, this must be discussed before you start rather than discovered later.
Discuss Seizure and Psychiatric History
Bupropion carries seizure risk and documented neuropsychiatric warnings. Seizure history, eating disorder history and mental health history are all directly relevant to whether Contrave is appropriate for you.
Check Insurance Before the Cash Programme
Eligible commercially insured patients may pay $20 to $199 per 30-day fill depending on copay obligation. That can be well below the $99 manufacturer rate. Run the coverage check first, then fall back to CurAccess.
Enrol in the CurAccess Programme if Paying Cash
The manufacturer states all patients may pay $99 or less, with free shipping through the CurAccess home delivery programme. Retail pricing outside the programme has been reported at $742 or more — there is no reason to pay it.
Titrate Gradually Over Several Weeks
Contrave escalates gradually to the maintenance dose, which is taken twice daily. Nausea, headache and constipation are common early. Report side effects rather than pushing through, and do not accelerate your own titration.
Set Realistic Expectations
Contrave produces less weight loss than GLP-1 therapy. It is an effective approved medication with a distinct mechanism, not a substitute that matches semaglutide or tirzepatide. Knowing that before starting prevents premature abandonment of a treatment that is working as intended.
Program Details at a Glance
| Detail | Contrave |
|---|---|
| Medication class | Combination oral weight-management medication: naltrexone HCl, an opioid antagonist, with bupropion HCl extended-release. |
| Approval status | FDA-approved for chronic weight management. |
| Eligibility | Adults meeting the approved BMI criteria, subject to clinical assessment. Contraindications include opioid use and factors relating to seizure risk. |
| Provider involvement | Prescription-only. Requires a prescribing clinician and follow-up during titration, particularly given the neuropsychiatric considerations. |
| Lab requirements | Determined by your clinician based on your history and comorbidities. |
| Pharmacy fulfillment | Standard retail and mail-order channels, plus the manufacturer CurAccess home delivery programme. Not a compounded product. |
| Dosing frequency | Extended-release tablet, titrated gradually over several weeks to a twice-daily maintenance dose. |
| Support services | Currax Pharmaceuticals operates the CurAccess savings and home delivery programme. Check current terms directly. |
| Membership fee | Not applicable — this is a medication. Any programme fee depends on the provider you obtain it through. |
| Medication fee | $99/month with free shipping through CurAccess; $20 to $199 per 30-day fill for eligible commercially insured patients. |
| Cancellation policy | Not applicable to the medication itself. Discuss discontinuation with your clinician rather than stopping abruptly, given the bupropion component. |
| Refund policy | Not applicable. Dispensed prescription medication is generally not returnable. |
| Insurance | Where insurance covers Contrave it may cost less than the $99 programme rate. Eligible commercially insured patients may pay $20 to $199 per 30-day fill. |
| HSA / FSA | Prescription costs are commonly HSA/FSA eligible. Confirm with your plan administrator and keep itemised receipts. |
Who Contrave Is Best For
✓ Best For:
- • Patients whose eating is craving-driven rather than driven by hunger volume
- • Anyone who cannot tolerate GLP-1 gastrointestinal side effects
- • Patients for whom GLP-1 therapy is unaffordable and who want an approved alternative
- • People who want a flat, published price with no dose escalation
- • Anyone who cannot or will not inject
- • Commercially insured patients whose copay brings the cost to $20 to $50 a month
✗ Not Best For:
- • Anyone taking opioid medication, including for pain management — naltrexone is contraindicated
- • Patients with a seizure history or other bupropion contraindications
- • Anyone seeking maximum weight loss where GLP-1 therapy is accessible and appropriate
- • Patients with a history of eating disorders, given bupropion considerations
- • People who want once-daily dosing — maintenance is twice daily
- • Anyone who would pay retail rather than using the manufacturer programme or insurance
Limitations to Know Before You Sign Up
- ⚠Naltrexone is contraindicated with opioid use, including opioid pain management. This is an absolute consideration rather than a caution, and it needs to be raised before starting.
- ⚠Bupropion carries seizure risk and documented neuropsychiatric warnings. Seizure history, eating disorder history and mental health history are all directly relevant to eligibility.
- ⚠Contrave produces less weight loss than GLP-1 therapy. It is an effective approved medication with a distinct mechanism, not a substitute that matches semaglutide or tirzepatide outcomes.
- ⚠Retail pricing outside the manufacturer programme has been reported around $742 to $836 for a common version. Patients who do not know about the CurAccess programme or a discount card can pay many times the necessary cost.
- ⚠The maintenance dose is taken twice daily, a higher pill burden than once-daily oral alternatives, and titration takes several weeks before reaching it.
- ⚠Common early side effects include nausea, headache and constipation. These are usually manageable with gradual titration but should be reported rather than tolerated silently.
Alternatives to Contrave
Qsymia
The other main FDA-approved oral weight-loss medication, at $70/month on 90-day prescriptions with around 10% weight loss in clinical reporting.
Wegovy / Ozempic
FDA-approved injectable semaglutide, with substantially greater weight loss than any oral option.
Mounjaro / Zepbound
FDA-approved weekly tirzepatide, the dual agonist with the greatest average weight loss of the approved options.
Found
A telehealth provider offering non-GLP-1 medication pathways for patients GLP-1s do not suit.
Frequently Asked Questions
How much does Contrave cost?
The manufacturer states the price of Contrave is $99 per month with free shipping through the CurAccess programme, and that all patients may pay $99 or less. Where insurance covers it, eligible commercially insured patients may pay $20 to $199 per 30-day fill of 120 pills or less depending on their copay obligation. Retail pricing outside the programme has been reported around $742 to $836.
How does Contrave work?
Contrave combines naltrexone, an opioid antagonist, with bupropion, an antidepressant with weight effects. Together they act on reward and craving pathways rather than on gastric emptying and satiety hormones the way GLP-1s do. For patients whose eating is craving-driven, that mechanistic difference can matter clinically.
Is Contrave as effective as Wegovy or Zepbound?
No. Contrave produces less weight loss than injectable GLP-1 therapy. It is a legitimate FDA-approved option with a completely different mechanism, which makes it a genuine alternative for patients GLP-1s do not suit — but it is not an equivalent substitute for patients who can access GLP-1 therapy.
Can I take Contrave if I use opioid pain medication?
No. Naltrexone is contraindicated with opioid use, including opioid pain management. Disclose every medication you take, and raise this specifically with your prescriber before starting. If you might need opioid pain relief in future, that also needs discussing.
What are the main risks?
Bupropion carries seizure risk and documented neuropsychiatric warnings, so seizure history, eating disorder history and mental health history are all directly relevant. Naltrexone is contraindicated with opioid use. Common early side effects include nausea, headache and constipation, usually manageable through gradual titration.
How often do I take Contrave?
It is an extended-release tablet titrated gradually over several weeks to a twice-daily maintenance dose. That is a higher pill burden than once-daily oral alternatives such as Qsymia, and the titration period requires patience before you reach the full dose.
Is the $99 price available to everyone?
The manufacturer states all patients may pay $99 or less through the CurAccess programme, with free shipping. Where insurance covers Contrave it may cost less. Check your insurance first, then use the manufacturer programme — there is no reason to pay reported retail prices of $742 or more.
Contrave or Qsymia?
They work differently and suit different patients. Qsymia produces around 10% weight loss, the highest of any oral medication, but topiramate is associated with birth defects and phentermine is a controlled substance. Contrave targets craving pathways and is contraindicated with opioid use and in patients at seizure risk. Which is appropriate is a clinical decision based on your history, not a price comparison.
The Bottom Line
Contrave earns 3.5 out of 5 stars — an approved, affordable oral medication doing something no GLP-1 does, at a price that has been remarkably stable while everything around it inflated.
The mechanistic difference is the real story. Naltrexone and bupropion act on reward and craving pathways rather than on gastric emptying and satiety hormones. For a patient whose eating is driven by craving rather than by hunger volume — and for a patient who could not tolerate GLP-1 gastrointestinal effects — Contrave is not a weaker version of semaglutide. It is a different approach to a different aspect of the problem.
The pricing is genuinely good. $99 a month with free shipping, the same at every titration stage, with the manufacturer stating all patients may pay $99 or less — and eligible commercially insured patients potentially paying as little as $20 per fill. Against reported retail pricing of $742 to $836, the gap between knowing about the CurAccess programme and not knowing about it is several hundred dollars a month.
What limits it is efficacy and eligibility. Contrave delivers less weight loss than GLP-1 therapy, the maintenance dose is twice daily, and the contraindications are substantial: naltrexone is contraindicated with opioid use, and bupropion carries seizure risk and neuropsychiatric warnings. Our recommendation: Contrave is well worth discussing if GLP-1s are unaffordable, untolerated, or clinically unsuitable, and particularly if craving rather than portion size is what you are fighting. Check your insurance first, then use the manufacturer programme. If GLP-1 therapy is accessible, note that Coreage RX offers semaglutide or tirzepatide at the same $99 with substantially greater expected weight loss. Qsymia is the other approved oral option to compare.
Disclosure:
This review is based on publicly available information including the manufacturer’s published Contrave and CurAccess programme materials, prescriber resources, FDA labelling information, and public pharmacy, discount programme and savings card pricing, current as of August 27, 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews; we have no relationship with Currax Pharmaceuticals. Pricing depends on insurance coverage, programme eligibility and pharmacy — confirm your actual cost directly. Naltrexone is contraindicated with opioid use and bupropion carries seizure risk and neuropsychiatric warnings; prescribing decisions belong entirely to a clinician who knows your history. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This review is for informational purposes only and is not medical advice, diagnosis, or treatment. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. Never start, stop, or change a prescription based on this page. If you experience severe abdominal pain, persistent vomiting, signs of an allergic reaction, or other concerning symptoms, seek medical care immediately. See our full medical disclaimer.
Or check out our top-rated provider